Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjhemonc logo
VJOncology
Logo
  • Home (current)
  • Diseases
    Genitourinary
    Lung
    Head and Neck
    Breast
    Gynecological
    Skin
    View all Diseases
    • Topics
      Treatment
      Early Diagnosis
      Nursing
      Pharmacy
      Supportive Care
      Policy
      View all Topics
      • Conferences
        NCRI
        2019
        ISOPP
        2019
        ESMO
        2019
        EONS
        2019
        ASCO
        2019
        ELCC
        2019
        View all Conferences
        • Features
        • Podcasts
          • About
          • Board
          • News
          • Sign Up
          • Contact

        biomarker

        2:28
        First-line treatment guidelines: combination strategy
        Laurence Albiges
        2:04
        NIVOREN GETUG-AFU 26: Updates and implications
        Laurence Albiges
        2:13
        The value of PD-L1 as a biomarker beyond lung cancers
        Kevin Harrington
        2:52
        OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
        Georgina Long
        3:00
        Biomarker-directed BISCAY data: durvalumab plus targeted therapies in mUC
        Thomas Powles
        1:18
        Vinorelbine in Mesothelioma: the upcoming VIM trial
        Dean Fennell
        2:12
        The omega score: an emerging biomarker for risk determination
        Hisham Mehanna
        3:08
        KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
        Barbara Burtness
        2:25
        Molecular aging and p16INK4a in testicular cancer survivors
        Maria Teresa Bourlon
        1:24
        How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?
        Jacob Kettle
        1:26
        Assessment and diagnostic workup for NSCLC in 2018
        Nathan Penell
        2:11
        Economic impact of NGS for NSCLC diagnostics
        Nathan Penell
        1:49
        Using immunotherapy wisely for prostate cancer
        Gerhardt Attard
        1:37
        Olaparib plus abiraterone for mCRPC: are biomarkers necessary?
        Gerhardt Attard
        3:34
        ABACUS trial: preoperative atezolizumab in urothelial carcinoma
        Thomas Powles
        2:18
        EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
        Thomas Powles
        • 1
        • 2
        • 3
        • 4
        • Next
        vjoncology logo VJOncology is intended for Healthcare Professionals only

        By choosing to continue, you are confirming that you are a healthcare professional

        VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

        Please enter your details if you would like to receive the latest oncology news and updates

        Continue
        Disease channels
        • Genitourinary
        • Lung
        • Head and Neck
        • Breast
        • Gynecological
        • Skin
        • View all
        Join our community

        Keep up-to-date via social media

        Sign up for email updates

        Get great new content delivered to your inbox

        Sign up
        mmp logo

        Magdalen Centre
        The Oxford Science Park
        Oxford OX4 4GA, United Kingdom

        VJOncology logo
        The content of VJOncology is intended for healthcare professionals
        • Cookie Policy
        • Privacy Policy
        • Terms of Use
        • Editorial Policy